Cipla slapped with Rs 53L GST penalty for alleged TRAN-1 credit misuse, plans legal challenge
Mumbai: Drug major Cipla Limited has disclosed that the Office of the Principal Commissioner of Central Goods & Services Tax (GST) and Central Excise in Lucknow has imposed a penalty of Rs 53,09,449 on the company. This penalty, under the provisions of the Central Goods and Services Tax Act, 2017, relates to the alleged improper use of TRAN-1 credit. The credit in question was availed by Cipla during the transition to the GST regime, and the GST Authority has claimed it was inadmissible under the law.
This disclosure, made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was communicated to stock exchanges, including BSE Limited and the National Stock Exchange of India, as well as to the Luxembourg Stock Exchange. Cipla received the official order dated November 13, 2024, on November 27, 2024, as detailed in a regulatory filing.
The GST Authority has alleged that Cipla availed inadmissible credit under the TRAN-1 mechanism, which was introduced during the transition to the GST regime. TRAN-1 credit allowed businesses to carry forward eligible tax credits from the pre-GST indirect tax system into the GST framework. The Authority has not only ordered the recovery of the disputed amount but has also imposed a penalty along with applicable interest under the CGST Act, 2017.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.